Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY2439821 · 3 trials · 1 indication
ACR20 responders are participants with at least 20% improvement from baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: Health Assessment Questionnaire-Disability Index (HAQ-DI) which measured participants perceived degree of difficulty performing daily activities, C-reactive Protein (CRP), Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), Patient's Global Assessment of Disease Activity-VAS(PtGADA-VAS), and Physician's Global Assessment of Disease Activity-VAS (PhGA-VAS). Missing values were imputed using Non-Responder Imputation (NRI). Percentage of participants achieving ACR20 response was calculated as: (number of ACR20 responders / number of participants treated) \* 100.
Data presented are the number of participants who experienced 1 or more AEs (all causalities and drug-related) and serious AEs (SAEs). A summary of SAEs and other non-serious AEs, regardless of causality is located in the Reported Adverse Events section of this report.
Clinically significant events were defined as serious and other non-serious adverse events. A summary of serious and all other non-serious adverse events is located in the Reported Adverse Event module.
| Arm | Type | Description |
|---|---|---|
| 3 mg LY2439821 (bDMARD-naive population) | EXPERIMENTAL | 3 milligrams (mg) LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60. \[Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD)\] |
| 10 mg LY2439821 (bDMARD-naive population) | EXPERIMENTAL | 10 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60. |
| 30 mg LY2439821 (bDMARD-naive population) | EXPERIMENTAL | 30 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60. |
| 80 mg LY2439821 (bDMARD-naive population) | EXPERIMENTAL | 80 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60. |
| 180 mg LY2439821 (bDMARD-naive population) | EXPERIMENTAL | 180 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60. |
| 80 mg LY2439821 (TNFa-IR population) | EXPERIMENTAL | 80 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60. \[Tumor Necrosis Factor Alpha-Inadequate Responder (TNFα-IR)\] |
| 180 mg LY2439821 (TNFa-IR population) | EXPERIMENTAL | 180 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60. |
| Placebo (bDMARD-naive population) | PLACEBO_COMPARATOR | Placebo at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60. |
| Placebo (TNFa-IR population) | PLACEBO_COMPARATOR | Placebo at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60. |
| 30 milligrams (mg) LY2439821 | EXPERIMENTAL | Participants will start receiving LY2439821 30 mg once every week for the first 3 doses and then once every 2 weeks until week 44. Investigators or its designees will increase the LY2439821 dose to 160 mg at any visit once the safety of LY2439821 180 mg is confirmed by the Data Review Meeting in Study I1F-JE-RHAL (NCT01253265). |
| 80 mg LY2439821 | EXPERIMENTAL | Participants will start receiving LY2439821 80 mg once every week for the first 3 doses and then once every 2 weeks until week 44. Investigators or its designees will increase the LY2439821 dose to 160 mg at any visit once the safety of LY2439821 180 mg is confirmed by the Data Review Meeting in Study I1F-JE-RHAL (NCT01253265). |
| 160 mg LY2439821 | EXPERIMENTAL | Participants will start receiving LY2439821 160 mg once every 2 weeks for the first 3 doses and then once every 4 weeks until Week 44. |
| 30 mg LY2439821 | EXPERIMENTAL | Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10 |
| 180 mg LY2439821 | EXPERIMENTAL | Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10 |
| Placebo | PLACEBO_COMPARATOR | Placebo is administered subcutaneously in the same manner as active drug in each dose group |
| 120 mg LY2439821 | EXPERIMENTAL | Administered subcutaneously at 240 mg as a single loading dose followed by 120 mg every week |
| Name | Type | Description |
|---|---|---|
| LY2439821 | BIOLOGICAL | Subcutaneous |
| Placebo | DRUG | Subcutaneous |
Inclusion Criteria: * You must be between the ages of 18 and 75 * You must have active RA Qualifications Specific to the bDMARD-naive Population: You must be regularly using methotrexate (MTX) for at least 12 weeks before your participation in this study Qualifications Specific to the TNFα-IR Po...
Top 20 of 28 competitors
LY2439821 is an investigational small molecule being studied for the treatment of rheumatoid arthritis, an autoimmune condition causing joint inflammation and pain. It is developed by Eli Lilly and Company and has completed clinical trials in patients with this condition, though it remains in clinical development and is not yet approved.
LY2439821 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker LLY. The drug is an investigational small molecule intended for rheumatoid arthritis and is currently in clinical development, with no approved status.
LY2439821 is in Phase 2 clinical development for rheumatoid arthritis. It has completed three trials, including a Phase 2 study and two Phase 1 studies, all of which are finished. The drug remains investigational and has not received FDA approval.
LY2439821 has completed three clinical trials for rheumatoid arthritis: NCT00966875, a Phase 2 study with 448 participants; NCT01236118, a Phase 1 study with 28 participants; and NCT01253265, a Phase 1 study with 32 participants. All trials are completed and were conducted in multiple countries, including the United States and Japan.
LY2439821 is the primary name for this investigational drug, and no alternative names have been reported. It is a small molecule being studied for rheumatoid arthritis by Eli Lilly and Company, and it is distinct from other drugs in the company's pipeline.